{"entity":{"id":"theo-260","kind":"drug","name":"THEO-260","aka":[],"tldr":"THEO-260 is an oncolytic virus from Theolytics Limited, in registered phase 2 trials for ovarian cancer.","summary":"THEO-260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Theolytics Limited, in ovarian cancer. An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of THEO-260","url":"https://clinicaltrials.gov/search?intr=THEO-260"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06618235"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"THEO-260","modality":"Oncolytic virus","mechanism":"An oncolytic virus, as described in the registry record: a virus engineered to infect and burst tumour cells and alert the immune system.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/theo-260/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"trial":[{"id":"nct06618235","kind":"trial","name":"Trial of THEO-260 in Ovarian Cancer Patients","route":"/trials/nct06618235/"}]}}